Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?: Figure 1.
Angela Huttner(University Hospital of Geneva), Jason A. Roberts(Université de Montpellier), Stephan Harbarth(University Hospital of Geneva), William Hope(University of Liverpool), Jeffrey Lipman(The University of Queensland)
Cited by 138
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
|Intensive Care Medicine|2020|1.1k